By Application
Hot products 
-
Mouse Anti-C5b-9 Recombinant Antibody (aE11) (CBMAB-AO138LY)
-
Human Anti-SARS-CoV-2 Spike Recombinant Antibody (CR3022) (CBMAB-CR014LY)
-
Mouse Anti-ATG5 Recombinant Antibody (9H197) (CBMAB-A3945-YC)
-
Mouse Anti-CCNH Recombinant Antibody (CBFYC-1054) (CBMAB-C1111-FY)
-
Mouse Anti-APOA1 Monoclonal Antibody (CBFYR0637) (CBMAB-R0637-FY)
-
Mouse Anti-BSN Recombinant Antibody (219E1) (CBMAB-1228-CN)
-
Mouse Anti-CD24 Recombinant Antibody (HIS50) (CBMAB-C10123-LY)
-
Mouse Anti-DMD Recombinant Antibody (D1190) (CBMAB-D1190-YC)
-
Mouse Anti-CD33 Recombinant Antibody (P67.6) (CBMAB-C10189-LY)
-
Rabbit Anti-CBL Recombinant Antibody (D4E10) (CBMAB-CP0149-LY)
-
Mouse Anti-CD33 Recombinant Antibody (6C5/2) (CBMAB-C8126-LY)
-
Rat Anti-ABCC11 Recombinant Antibody (V2-179001) (CBMAB-A0236-YC)
-
Rat Anti-EMCN Recombinant Antibody (28) (CBMAB-E0280-FY)
-
Rat Anti-FABP3 Recombinant Antibody (CBXF-2299) (CBMAB-F1612-CQ)
-
Rabbit Anti-AKT2 (Phosphorylated S474) Recombinant Antibody (V2-556130) (PTM-CBMAB-0605LY)
-
Mouse Anti-COL1A2 Recombinant Antibody (CF108) (V2LY-1206-LY626)
-
Mouse Anti-ASH1L Monoclonal Antibody (ASH5H03) (CBMAB-1372-YC)
-
Mouse Anti-DHFR Recombinant Antibody (D0821) (CBMAB-D0821-YC)
-
Rabbit Anti-ALOX5AP Recombinant Antibody (CBXF-1219) (CBMAB-F0750-CQ)
-
Mouse Anti-8-oxoguanine Recombinant Antibody (V2-7697) (CBMAB-1869CQ)
Skin Cancer (SCC)
Fig.1 Squamous cell skin cancer
Squamous-cell skin cancer, also named as cutaneous squamous-cell carcinoma (cSCC), is one of the typical types of skin cancer along with melanoma and basal cell cancer. Normally, it presents as a hard lump with a scaly top but can also deteriorate into an ulcer. Onset is often several months. Squamous-cell skin cancer is more likely to spread to distant areas comparing with basal cell cancer. The greatest risk factor is the high total exposure to ultraviolet radiation from the sun. Squamous cell cancers happening in the ears and lip have high possibilities of local recurrence and distant metastasis (about 20–50%). SCCs represent around 20% of the non-melanoma skin cancers, but on account of their more obvious nature and growth rates, they stands for 90% of all head and neck cancers that are primarily presented. CD10, as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma, has been studied.
Loading...
Compare
